Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?

Simple item page
dc.contributor.authorMerlo Pich, Emilio
dc.contributor.authorJeromin, Andreas
dc.contributor.authorFrisoni, Giovanni B
dc.contributor.authorHill, Derek
dc.contributor.authorLockhart, Andrew
dc.contributor.authorSchmidt, Mark E
dc.contributor.authorTurner, Martin R
dc.contributor.authorMondello, Stefania
dc.contributor.authorPotter, William Z
dc.date.accessioned2020-02-07T13:31:05Z
dc.date.available2020-02-07T13:31:05Z
dc.date.issued2014-12-08
dc.description.abstractThis review provides perspectives on the utility of magnetic resonance imaging MRI as a neuroimaging approach in the development of novel treatments for Alzheimer s disease These considerations were generated in a roundtable at a recent Wellcome Trust meeting that included experts from academia and industry It was agreed that MRI either structural or functional could be used as a diagnostic for assessing worsening of disease status for monitoring vascular pathology and for stratifying clinical trial populations It was agreed also that MRI implementation is in its infancy requiring more evidence of association with the disease states test retest data better standardization across multiple clinical sites and application in multimodal approaches which include other imaging technologies such as positron emission tomography electroencephalography and magnetoencephalography
dc.identifier.urihttp://dx.doi.org/10.1186/alzrt276
dc.identifier.urihttps://lib.digitalsquare.io/xmlui/handle/123456789/14551
dc.relation.uriAlzheimer's research And therapy
dc.titleImaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?en
dcterms.abstractThis review provides perspectives on the utility of magnetic resonance imaging MRI as a neuroimaging approach in the development of novel treatments for Alzheimer s disease These considerations were generated in a roundtable at a recent Wellcome Trust meeting that included experts from academia and industry It was agreed that MRI either structural or functional could be used as a diagnostic for assessing worsening of disease status for monitoring vascular pathology and for stratifying clinical trial populations It was agreed also that MRI implementation is in its infancy requiring more evidence of association with the disease states test retest data better standardization across multiple clinical sites and application in multimodal approaches which include other imaging technologies such as positron emission tomography electroencephalography and magnetoencephalography
dcterms.contributorMerlo Pich, Emilio
dcterms.contributorJeromin, Andreas
dcterms.contributorFrisoni, Giovanni B
dcterms.contributorHill, Derek
dcterms.contributorLockhart, Andrew
dcterms.contributorSchmidt, Mark E
dcterms.contributorTurner, Martin R
dcterms.contributorMondello, Stefania
dcterms.contributorPotter, William Z
dcterms.identifierhttp://dx.doi.org/10.1186/alzrt276
dcterms.relationAlzheimer's research And therapy
dcterms.titleImaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?en
Files
Collections
mhealth Evidence